SEC Comment Letter for Cocrystal Pharma, Inc. (COCP) (CIK 0001412486) (COCP) — Oct 13, 2017
Cocrystal Pharma, Inc. (COCP) (CIK 0001412486)
Date: Oct. 13, 2017 · CIK: 0001412486 · Accession: 0000000000-17-036342
AI Filing Summary & Sentiment
Reasoning
Letter
October 12, 2017 James Martin Chief Financial Officer Cocrystal Pharma, Inc. 1860 Montreal Road Tucker, GA 30084 Cocrystal Pharma, Inc. Information Statement on Schedule 14C Filed October 4, 2017 File No. 000-55158Re: Dear Mr. Martin: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence by the staff. Division of Corporation Finance Office of Healthcare & Insurance cc: Michael D. Harris, Esq. - Nason, Yeager, Gerson, White & Lioce, P.A.
Show Raw Text
October 12, 2017 James Martin Chief Financial Officer Cocrystal Pharma, Inc. 1860 Montreal Road Tucker, GA 30084 Cocrystal Pharma, Inc. Information Statement on Schedule 14C Filed October 4, 2017 File No. 000-55158Re: Dear Mr. Martin: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence by the staff. Division of Corporation Finance Office of Healthcare & Insurance cc: Michael D. Harris, Esq. - Nason, Yeager, Gerson, White & Lioce, P.A.